Literature DB >> 9147379

Ryanodine receptors from rabbit skeletal muscle are reversibly activated by rapamycin.

G P Ahern1, P R Junankar, A F Dulhunty.   

Abstract

In this report we demonstrate that the immunosuppressive drug, rapamycin, can reversibly activate the skeletal muscle ryanodine receptor calcium release channel (RyR) in terminal cisternae vesicles incorporated into planar lipid bilayers. This reveals a second mechanism of activation of RyRs by rapamycin. Irreversible channel activation and openings to subconductance levels are seen when rapamycin forms a complex with and removes the tightly bound 12 kDa FK506-binding protein (FKBP12) from the RyR. We show here that micromolar rapamycin activates RyRs which were previously 'stripped' of > 95% of their FKBP12s. Rapamycin caused a 6-fold increase in mean current, which was largely reversible, but no increase in the fraction of openings to subconductance levels. Therefore native RyRs, stripped of FKBP12, are directly activated by the macrocyclic lactone, rapamycin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9147379     DOI: 10.1016/s0304-3940(97)00193-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

Review 1.  FK506-binding proteins 12 and 12.6 (FKBPs) as regulators of cardiac Ryanodine Receptors: Insights from new functional and structural knowledge.

Authors:  Luis A Gonano; Peter P Jones
Journal:  Channels (Austin)       Date:  2017-06-21       Impact factor: 2.581

2.  Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function.

Authors:  Kristin P Bibee; Ya-Jian Cheng; James K Ching; Jon N Marsh; Allison J Li; Richard M Keeling; Anne M Connolly; Paul T Golumbek; Jacob W Myerson; Grace Hu; Junjie Chen; William D Shannon; Gregory M Lanza; Conrad C Weihl; Samuel A Wickline
Journal:  FASEB J       Date:  2014-02-05       Impact factor: 5.191

3.  Augmentation of SR Ca(2+) release by rapamycin and FK506 causes K(+)-channel activation and membrane hyperpolarization in bladder smooth muscle.

Authors:  T Weidelt; G Isenberg
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

4.  Oxidation and reduction of pig skeletal muscle ryanodine receptors.

Authors:  C S Haarmann; R H Fink; A F Dulhunty
Journal:  Biophys J       Date:  1999-12       Impact factor: 4.033

5.  Activation and inhibition of skeletal RyR channels by a part of the skeletal DHPR II-III loop: effects of DHPR Ser687 and FKBP12.

Authors:  A F Dulhunty; D R Laver; E M Gallant; M G Casarotto; S M Pace; S Curtis
Journal:  Biophys J       Date:  1999-07       Impact factor: 4.033

6.  Effects of ivermectin and midecamycin on ryanodine receptors and the Ca2+-ATPase in sarcoplasmic reticulum of rabbit and rat skeletal muscle.

Authors:  G P Ahern; P R Junankar; S M Pace; S Curtis; J A Mould; A F Dulhunty
Journal:  J Physiol       Date:  1999-01-15       Impact factor: 5.182

7.  FKBP12 activates the cardiac ryanodine receptor Ca2+-release channel and is antagonised by FKBP12.6.

Authors:  Elena Galfré; Samantha J Pitt; Elisa Venturi; Mano Sitsapesan; Nathan R Zaccai; Krasimira Tsaneva-Atanasova; Stephen O'Neill; Rebecca Sitsapesan
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

8.  Effects of FK506 on ca release channels (review).

Authors:  Terutaka Ozawa
Journal:  Perspect Medicin Chem       Date:  2008-03-18

9.  FKBP12.6 activates RyR1: investigating the amino acid residues critical for channel modulation.

Authors:  Elisa Venturi; Elena Galfré; Fiona O'Brien; Samantha J Pitt; Stuart Bellamy; Richard B Sessions; Rebecca Sitsapesan
Journal:  Biophys J       Date:  2014-02-18       Impact factor: 4.033

10.  Effect of Calstabin1 depletion on calcium transients and energy utilization in muscle fibers and treatment opportunities with RyR1 stabilizers.

Authors:  Anke Breckner; Magdalena Ganz; David Marcellin; Jens Richter; Nicole Gerwin; Martin Rausch
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.